Guardant Health Announces ECLIPSE Study Update Call on May 9, 2023

Rhea-AI Summary

Guardant Health will report additional data from its pivotal ECLIPSE study at Digestive Disease Week. The webcast and conference call will be available for replay.

Positive

• Investors can access live audio of the webcast on the company website. The additional data from the ECLIPSE study may provide positive insights into Guardant Health's precision oncology technology.

Negative

• No negative takes found.

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report additional data from its pivotal ECLIPSE study at Digestive Disease Week (DDW) on Tuesday, May 9, 2023. The company will host a webcast and conference call with primary investigators of the study and other cancer screening experts beginning at 11:00 a.m. ET / 8:00 a.m. PT.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event.

Materials related to the DDW presentation will be available at approximately 10:15 a.m. ET / 7:15 a.m. PT on the “Key Publications” section of the company website at: www.guardanthealth.com.

About Digestive Disease Week®

Digestive Disease Week (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting from May 6-9, 2023. The meeting showcases more than 3,100 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer, and Guardant Reveal™ for early-stage cancer. The Guardant Health screening portfolio, including the Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com and follow the company on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230504006138/en/

Investor Contact:

Alex Kleban

investors@guardanthealth.com

+1 657-254-5417

Media Contact:

Michael Weist

press@guardanthealth.com

+1 317-371-0035

Source: Guardant Health, Inc.

FAQ

When will Guardant Health report additional data from its ECLIPSE study?

Guardant Health will report additional data from its ECLIPSE study at Digestive Disease Week on Tuesday, May 9, 2023.

Where can investors access the webcast of the conference call?

Investors can access live audio of the webcast on the 'Investors' section of the company website at www.guardanthealth.com.

Will the webcast be available for replay?

Yes, the webcast will be archived and available for replay after the event.

Where can materials related to the DDW presentation be found?

Materials related to the DDW presentation will be available on the 'Key Publications' section of the company website at www.guardanthealth.com at approximately 10:15 a.m. ET / 7:15 a.m. PT.